Coherus Oncology, Inc. (NASDAQ:CHRS) is a biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company operates in a competitive landscape alongside peers like Atara Biotherapeutics, FibroGen, MacroGenics, CytomX Therapeutics, and Blueprint Medicines. These companies are also engaged in the development of treatments for various diseases, making the industry highly competitive.
In evaluating Coherus Oncology's financial performance, the Return on Invested Capital (ROIC) is a critical metric. Coherus has a negative ROIC of -153.12%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 11.27%. This indicates that Coherus is not generating enough returns to cover its cost of capital, suggesting inefficiencies in how it uses its capital.
Comparatively, Atara Biotherapeutics (NASDAQ:ATRA) demonstrates a strong financial position with a ROIC of 222.66% and a WACC of 5.98%. This results in a ROIC to WACC ratio of 37.26, highlighting Atara's ability to generate substantial returns on its invested capital. This efficiency in capital utilization sets Atara apart from its peers.
Other peers like FibroGen, MacroGenics, CytomX Therapeutics, and Blueprint Medicines also show negative ROICs, but none as low as Coherus. For instance, FibroGen has a ROIC of -50.80% and a WACC of 7.44%, resulting in a ROIC to WACC ratio of -6.83. This indicates that while FibroGen is also struggling, it is not as inefficient as Coherus.
The comparison of ROIC and WACC among these companies underscores the importance of these metrics in assessing financial health. Coherus's negative ROIC to WACC ratio of -13.59 is a red flag for investors, suggesting that the company needs to improve its capital utilization to enhance its financial performance.
